PDGFRB and neoplasm: In renal cell carcinoma, the inactivation of Von Hippel-Lindau (VHL) promotes the H3K18la modification of platelet-derived growth factor receptor β (PDGFRβ), activating its transcription and driving tumor progression by H3K18la-PDGFRβ positive feedback loop (91).